LIPOSOMAL INHALATION CHEMOTHERAPY
- The pre-clinical studies conducted in Rutgers University, New Jersey prove the efficacy of Liposomal Doxorubicin vs Doxorubicin.
- This patented approach will bring new treatment option via patented controlled nebulizer – mask device mainly for some rare indications in cancer.
- A successful Phase I and Phase II multicenter multinational clinical trials to be completed within the next 2 years to get Orphan Drug Designation for Small Cell Lung Cancer (SCLC) and Pediatric Lung Cancers.
- The success of Liposomal Inhalation Chemotherapy means possible treatment of many cancer indications in smaller Health Centers that will create further advantages for logistically disadvantaged cancer patients.